Background: Although both tipranavir and darunavir are important options for the management of patients with multidrug resistant HIV, there are at present no studies comparing the effectiveness and safety of these 2 antiretroviral drugs in this population of patients. Objective: To compare the effectiveness and safety of ritonavir (TPV/r)-and darunavir/ritonavir (DRV/ r)-based therapies in treatment-experienced patients (n ¼ 38 and 47, respectively). Methods: Multicenter, retrospective cohort study. Results: The median baseline viral load and CD4 count were 4.7 copies/mL (interquartile range [IQR] 4.3, 5.2) and 168 cells/mm 3 (IQR 80, 252) for TPV/r patients and 4.7 copies/mL (IQR 3.7, 5.1) and 171 cells/mm 3 (IQR 92, 290) for DRV/r patients. The median number of years on antiretroviral therapy (ART) prior to starting DRV/r or TPV/r were 12.7 (10.2-15.5) and 10.5 (8.4-12.6), respectively (P < .01). Current raltegravir (RAL) use (odds ratio [OR] 5.53, 95% CI 1.08-28.34) was significantly associated with virologic suppression at week 24 in multivariable logistic regression models, whereas the use of TPV/r was not significantly associated with virologic suppression compared to DRV/r (OR 0.93, 95% CI 0.27-3.18, P ¼ .91). Conclusion: No significant difference was observed between DRV/r and TPV/r in terms of virologic suppression.
Introduction
The introduction of protease inhibitors (PIs) for the management of HIV infection and the subsequent adoption of PI-based combination antiretroviral therapy (cART) as the standard of care for HIV-infected patients resulted in profound reductions in disease-related morbidity and mortality. 1, 2 However, the widespread uptake of PI-based cART for HIV-infected patients has also presented clinicians with multiple challenges, including the emergence of drug resistance and treatment-associated complications such as metabolic adverse effects, drug interactions, and fat redistribution syndromes. [3] [4] [5] The development of new PIs with significant antiviral activity in individuals with extensive class resistance has, therefore, emerged as an issue of paramount importance in the field of HIV therapeutics.
Tipranavir (TPV) and darunavir (DRV) are the most recently approved PIs, and each demonstrates potent in-vitro and in-vivo activity against strains of HIV-1 which have accumulated multiple mutations associated with resistance to this class of drugs. 6, 7 When combined with low, non-therapeutic doses of ritonavir (/r), each drug has been shown to be superior to comparator PIs in randomized controlled trials of treatment-experienced patients. 8, 9 Although both TPV and DRV represent important new options for the management of patients with multi-PI-resistant HIV, currently there are no studies comparing the effectiveness and safety of these 2 drugs in this population of patients. The purpose of our study was to compare the virologic and immunologic effectiveness of TPV/r and DRV/r-based cART in treatment-experienced patients in clinical practice.
Methods

Study Population and Study Design
We conducted a retrospective cohort study of HIV-infected adults who were receiving either TPV/r-or DRV/r-based cART at 4 sites in Toronto, Ontario, Canada. Participating sites included 2 primary care clinics specializing in the provision of HIV-related care and 2 hospital-based HIV specialty clinics. Patients receiving either TPV/r or DRV/r were identified by review of patient charts or electronic databases at the respective sites. Patients were eligible for inclusion in the analysis if they were antiretroviral-experienced, had received either TPV/r or DRV/r for a minimum of 1 month, had a viral load ([VL] Chiron 3.0) of >50 copies/mL prior to initiating TPV/r-or DRV/r-based therapy and had follow-up laboratory evaluation for at least 60 days following the initiation of therapy. Antiretroviral drugs agents used in conjunction with TPV/r and DRV/ r were selected based on treatment history and genotypic resistance testing at the discretion of the treating physician.
Virologic and Immunologic End Points
The primary end-point of the study was the proportions of patients in each group with plasma VLs of <50 copies/mL at week 24 of follow-up. The secondary end point of the study was time to virologic suppression (plasma VL <50 copies/ mL), which was defined as the duration from starting either TPV/r-or DRV/r-based therapy to the first date when plasma VL was <50 copies/mL for 2 consecutive measurements. Participants who did not achieve virologic suppression during the study period were censored at the date of last follow-up.
For patients who achieved a VL of <50 copies/mL during follow-up, the durability of the virologic response was assessed by determining the time to virologic rebound while receiving TPV/r-or DRV/r-based therapy. Time to virologic rebound was defined as the duration from the first date of virologic suppression to the first date of plasma VL !50 copies/mL on 2 consecutive samplings without a change in the regimen. Patients who did not experience virologic rebound during the study period were censored at the date of last follow-up.
Additional end points included changes in CD4 count from baseline to weeks 24 and 48 following the initiation of either TPV/r-or DRV/r-based therapy.
Adverse Events
The primary toxicity end points of interest were the occurrence of grade 2 elevations in serum alanine transaminase (ALT), cholesterol, or triglycerides, according to the National Institute of Allergy and Infectious Diseases (NIAID) Division of AIDS toxicity grading tables. 10 
Statistical Analysis
All statistical analyses were performed using SAS Version 9.1 (SAS Institute, Cary, North Carolina). Baseline characteristics of the 2 groups were compared using the Wilcoxon rank sum test for continuous variables and the chi-square test for categorical variables. Wilcoxon signed rank tests were used to determine whether changes over time in serum ALT, serum cholesterol, and serum triglycerides were significantly different from baseline within each group. Median times to virologic suppression and rebound were determined using Kaplan-Meier curves, and differences between the 2 groups with respect to these outcomes were assessed with the log rank test. Cox proportional hazards models were used to estimate the relative risks of virologic suppression and virologic rebound associated with demographic, laboratory, and genotypic variables. The assumptions of the Cox proportional hazards model were tested for each variable. Logistic regression analysis was used to estimate the odds of attaining virologic suppression at 24 weeks of follow-up.
Results
Patient Characteristics
A total of 113 patients were identified as having taken either TPV/r-or DRV/r-based therapy at 1 of the 4 clinical sites. Of these, a total of 28 patients were excluded from the analysis due to having a VL <50 copies/mL at baseline (n ¼ 19), having less than 60 days follow-up (n ¼ 8) or both (n ¼ 1). Eighty-five patients were, therefore, included in the analysis; of the 85 patients, 38 were receiving TPV/r-and 47 were receiving DRV/ r-based regimens. The median number of weeks of follow-up and number of plasma VL measurements performed were 113 weeks (interquartile range [IQR] 72, 132) and 11 (IQR 8, 13) for TPV/r and 36 weeks (IQR 24, 59) and 5 (IQR 4, 8) for DRV/r.
The baseline characteristics of the 2 groups are summarized in Table 1 . Although there were no significant differences between the 2 groups with respect to selected demographic variables such as age, VL, and CD4 count, the 2 groups differed with respect to variables such as the median number of previous antiretroviral drugs used (4 [IQR 3, 5] for TPV/r vs 4 [IQR 4, 5] for DRV/r; P < .01) and the median number of years on ART (10.5 [IQR 8.4, 12.6] for TPV/r vs 12.7 [IQR 10.2, 15.5] for DRV/r; P < .01). In addition, differences in the nature of the optimized background cART use were observed between the 2 groups. Specifically, the use of enfuvirtide (ENF) was significantly more common among patients receiving TPV/r (76% vs 47%; P < .01), whereas concomitant receipt of raltegravir (RAL) (51% vs 0%; P < .0001), etravirine (ETR) (50% vs 0%; P ¼ .0006), or nonnucleoside reverse transcriptase inhibitors ([NNRTIs] 67% vs 21%; P < .0001) was significantly more common among patients receiving DRV/r.
Baseline Resistance Testing
Baseline genotypic and virtual phenotypic resistance testing was available for 38 (100%) patients receiving TPV/r and 46 (98%) patients receiving DRV/r. Twenty-five (66%) and 13 (34%) patients on TPV/r had either 0 to 2 or 3 to 5 of the 21 mutations associated with reduced susceptibility to TPV/r-based therapy. For DRV/r, the numbers of patients with 0 to 2, 3 or !4 of the 11 mutations associated with reduced susceptibility to DRV/r were 40 (87%), 3 (7%), and 3 (7%).
Virologic Response
The numbers of patients receiving TPV/r and DRV/r and who attained a plasma VL below 50 copies/mL at least once during follow-up were 31 (82%) and 37 (79%), respectively (P ¼ .79). The corresponding numbers of patients on TPV/r and DRV/r achieving sustained virologic suppression with 2 or more sequential VL results below 50 copies/mL were 28 (74%) and 34 (72%; P ¼ .89). Following 24 weeks of follow-up, 67.6% of patients receiving DRV/r and 42.1% of patients receiving TPV/r had a VL of <50 copies/mL (P ¼ .03). The univariate logistic regression models identified several predictors of virologic suppression at week 24 ( Table 2 ). In a multivariable logistic regression analysis (Table 2) , only concurrent RAL use (adjusted odds ratio [aOR] 5.53, 95% CI 1.08, 28.34, P ¼ .04) remained significantly associated with virologic suppression at week 24, whereas the use of TPV/r was not significantly associated with this end point compared to DRV/r (aOR 0.93, 95% CI 0.27-3.18, P ¼ .91).
The unadjusted median times to virologic suppression were 29.4 (IQR 21.1, 93.9) and 15.3 (IQR 6.7, 43.9) weeks for TPV/r-and DRV/r-based regimens, respectively (P ¼ .01). The probability of virologic suppression after dividing patients on DRV/r according to whether their regimen contained raltegravir is shown in Figure 1 . 
Immunologic Response
The median increases in CD4 counts from baseline to week 24 were 110 cells/mm 3 (IQR 55, 180) and 77.5 cells/mm 3 (IQR 12.5, 147.5) for TPV/r and DRV/r, respectively (P ¼ .06). Respective figures for change from baseline to week 48 were 96 cells/mm 3 (IQR 67, 243) and 52 cells/mm 3 (IQR 1, 106; P < .01). Among 48 patients with a CD4 count <200 cells/mm 3 at baseline, 29 patients attained a sustained CD4 count !200 cells/mm 3 (at least 2 consecutive measurements) during follow-up. The median times to attain a CD4 count !200 mm 3 among patients with baseline levels below this threshold were 29 weeks and 37 weeks in the TPV/r and DRV/r groups, respectively (log rank test P ¼ .53).
Adverse Effects
Baseline levels of serum ALT, total cholesterol, and triglycerides are summarized in Table 1 . The median number of follow-up measurements of ALT, total cholesterol, and triglycerides were 9, 5, and 5 for patients on TPV/r and 4, 2, and 2 for patients on DRV/r. Through 48 weeks of follow-up, grade 3 or higher increases in serum ALT were observed in 3 (8%) and 1 (2%) patients receiving TPV/r and DRV/r, respectively (P ¼ .32; Table 4 ). Similarly, no significant difference was noted between the 2 groups with respect to median changes in serum ALT level from baseline to week 48 (P ¼ .09). All 4 patients with grade 3 or higher ALT were coinfected with either the hepatitis B (n ¼ 2) or hepatitis C (n ¼ 2) virus. Overall, no significant differences between the 2 groups were observed in the numbers of patients ever attaining a grade 2 or higher serum cholesterol or triglyceride level through 48 weeks follow-up (Table 4 ). Specifically, 8 (22%) and 7 (15%) TPV/r and DRV/r patients had a grade 2 or higher cholesterol (P ¼ .57), whereas respective figures for grade 2 triglyceride levels were 8 (22%) and 6 (13%; P ¼ .38). The median change in serum cholesterol from baseline through week 48 was not significantly different between the 2 groups, whereas it was significant in triglycerides (0.5 mmol/L [IQR À0.2, 1.5] for TPV/r and À0.7 mmol/L [IQR À3.7, À0.3] for DRV/r, P ¼ .02).
Patient Disposition
A total of 17 (44.7%) patients discontinued TPV/r following a median of 80 weeks (IQR 57, 103) of therapy. Reasons for discontinuing TPV/r were available for 11 of the patients, which included virologic failure (n ¼ 6), injection site reactions associated with concomitant ENF use (n ¼ 2), hepatotoxicity (n ¼ 2), and pancreatitis (n ¼ 1). Of the 6 patients with treatment failure, all were using enfuvirtide therapy. In terms of DRV/r, 5 (10.6%) patients discontinued therapy following a median of 26 weeks (IQR 2, 51) of therapy. Reasons for termination of therapy were provided for 4 patients, which included death (n ¼ 1), severe hypersensitivity reaction possibly related to DRV/r (n ¼ 1), fatigue and weight gain (n ¼ 1), and lethargy (n ¼ 1).
Discussion
Our study provides the first published data comparing the effectiveness and safety of TPV/r-and DRV/r-based regimens in a clinical setting. Although DRV/r has largely supplanted TPV/r as the preferred PI in patients with extensive resistance to this class, our findings suggest that TPV/r remains a viable option in the setting of DRV/r intolerance or reduced susceptibility, given the distinctive resistance profiles of the 2 drugs. 11 Although the 2 groups were similar with respect to baseline immunologic and virologic parameters, important differences existed in the degree of treatment experience, baseline genotypic sensitivity, and concomitant antiretroviral drug use. Most notably, approximately one half of the DRV/r patients received the HIV integrase inhibitor RAL as part of their treatment regimen, in contrast to none of the patients receiving TPV/r. We surmise that this difference is likely attributable to the timing in which TPV and DRV were rendered available to clinicians. Since TPV availability preceded that of DRV and RAL, patients initialized and stabilized on TPV/r-based therapy did not have access to the integrase inhibitor and were, therefore, more likely to receive ENF as part of their regimen. The imbalance in RAL use between the 2 groups may have accounted for the shorter time to virologic suppression observed among patients receiving DRV/r-based therapy, as no difference in this outcome was observed between groups following adjustment for RAL use in the Cox proportional hazards models. These findings are in keeping with previously published data describing rapid virologic suppression with RAL relative to comparator drugs. 12 In addition, although a significantly higher proportion of patients receiving DRV/r had attained virologic suppression at week 24, no difference between the 2 groups was observed with respect to this outcome following adjustment for RAL use in the multivariable logistic regression analysis. Thus, TPV/r and DRV/r appeared comparable when comparisons of all virologic endpoints were examined. However, given our relatively small sample size, we cannot with certainty rule out the possibility of type II errors when between group comparisons were made. In addition, it is important to note that virologic failure was cited as a reason for discontinuation of therapy in 6 patients receiving TPV/r, as compared to none of the patients receiving DRV/r-based treatment. Although it is difficult to discern precisely why this pattern was observed, it is possible that the availability of newer drugs in concert with DRV permitted for the assembly of more robust background therapy.
Patients receiving TPV/r had a significantly greater increase in CD4 count from baseline to week 48 relative to patients receiving DRV/r. Although the reasons accounting for this observation are clearly speculative, given the nature of our study, it is possible that the greater use of ENF among patients receiving TPV/r was associated with an immunological advantage for this group. Previous studies have documented immunologic benefits associated with ENF therapy that may be independent of the drug's effect on VL. [13] [14] [15] Aside from changes in serum triglycerides, laboratory dyscrasias of interest were not observed more frequently in one group relative to another. In addition, both drugs appeared to be well tolerated in our cohorts of patients, with treatmentassociated adverse reactions leading to termination of therapy in a small subset of patients receiving either drug. However, we are limited in drawing firm conclusions about the relative safety of these PI-based regimens, given the small sample size of our cohort. When both DRV/r and TPV/r were studied in comparison to other boosted PI-based regimens, rates of selected grades 3 and 4 laboratory abnormalities occurred at a higher incidence in each of the DRV/r and TPV/r arms relative to their respective comparators. 8, 9 Specifically, the rates of grade 3 or 4 increases in serum triglycerides, lipase, and total cholesterol in the POWER trials were 15%, 5%, and 7%, for patients randomized to DRV. Respective figures for patients in the comparator arms were 7%, 1%, and 2%. Similarly, grade 3 or 4 increases in serum triglycerides, cholesterol, ALT, and AST occurred in 30.8%, 4.3%, 10.1%, and 6.3% of patients randomized to TPV in the RESIST studies, compared with 23.1%, 0.7%, 3.3%, and 2.9% or patients randomized to comparator treatments. However, a randomized trial comparing the 2 drugs directly has yet to be performed and will be required to fully delineate the merits and drawbacks of each drug. Our study has several limitations, including its retrospective design, small sample size, and lack of randomization. In addition, patients in both arms were unlikely to have high levels of resistance to either agent, given the small number of drugspecific mutations accrued for both drugs prior to initiating therapy. Furthermore, the majority of our cohort comprised men. It is, therefore, not possible to extrapolate our findings with respect to the relative safety and effectiveness of each PI to women. However, data from this study are still clinically relevant, given the lack of comparative trials of DRV/r-and TPV/r-based regimens. In addition, observational studies may more closely approximate the effects of a specific treatment in clinical practice, since patients are assigned therapy based on individual characteristics rather than randomization. Although cross-study comparisons of the efficacy of DRV/r and TPV/r have been drawn and published, these data are difficult to interpret, given the inherent drawbacks associated with such approaches. 16 Our clinically based study provides reassurance that both drugs are important, effective additions to the antiretroviral arsenal when used according to patientspecific genotypic-resistant profiles and in conjunction with the best available background regimens.
In conclusion, our study provides important comparative data of the effectiveness, durability, and safety of TPV/r-and DRV/r-based regimens in a clinical setting. Following multivariable adjustment, no significant difference was observed between TPV/r and DRV/r in terms of virologic suppression. Although our patients were not randomized to individual treatments, this study represents the only available analysis comparing these important third-generation PIs. Additional data from observational studies or controlled trials comparing the 2 drugs would better clarify the role each drug can play in the management of treatment-experienced HIV-infected patients. Change from baseline to week 48 ALT, mmol/L À1.0 (À10.5-11.5) 16 À6.0 (À19.5-1.0) 32 2.5 (À10.0-19.5) .09 Total cholesterol, mmol/L 0.6 (À0.5-1.0) 12 0.1 (À1.9-0.8) 23 0.7 (À0.4-1.1) .10 TGs, mmol/L À0.1 (À0.8-0.9) 12 À0.7 (À3.7-0.3) 23 0.5 (À0. 
